Every Form 4 that Acrivon Therapeutics, Inc. (ACRV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACRV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRV filings page.
Acrivon Therapeutics insiders reported tax-related share dispositions tied to restricted stock unit vesting. The filing shows 1,302 shares of Common Stock disposed at $1.63 per share, leaving 2,094,469 shares owned following this transaction.
A separate indirect transaction reports a tax-withholding disposition of 579 Common Stock shares at $1.63 per share, with 314,127 shares owned indirectly afterward. Footnotes explain shares were withheld by the issuer to satisfy mandatory tax withholding and that certain holdings are through a spouse, with each spouse disclaiming beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation. On 01/17/2026, 659 shares of common stock were withheld at a price of $1.98 per share to cover mandatory tax withholding when her restricted stock units vested. After this transaction, she beneficially owned 33,896 shares of Acrivon common stock, held directly. This type of transaction does not represent an open-market sale but an automatic tax-related adjustment.
Acrivon Therapeutics’ President and CEO, Dr. Peter Blume-Jensen, reported buying 49,000 shares of common stock on January 14, 2026, in an open-market purchase at a weighted average price of $1.676 per share. The trades were executed in multiple lots at prices ranging from $1.66 to $1.68 per share. Following this transaction, he directly holds 2,095,771 common shares.
The filing also reports 314,706 common shares held indirectly through co-founder and EVP Dr. Kristina Masson. Footnotes state that Dr. Masson disclaims beneficial ownership of Dr. Blume-Jensen’s directly held shares, and Dr. Blume-Jensen likewise disclaims beneficial ownership of Dr. Masson’s shares, except to the extent of each spouse’s pecuniary interest.
Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported an open-market purchase of the company’s common stock. On January 14, 2026, he bought 8,832 shares of Acrivon common stock in a series of trades at a weighted average price of $1.6983 per share, with individual trade prices ranging from $1.695 to $1.7086. Following this transaction, he beneficially owned 20,983 shares of Acrivon common stock, held in direct ownership.
Acrivon Therapeutics, Inc. Chief Operating Officer Eric Devroe reported an open-market purchase of company stock. On 01/13/2026, he bought 10,000 shares of Acrivon common stock at a weighted average price of $1.7218 per share, executed in multiple trades within a price range of $1.719 to $1.7268. Following this purchase, he beneficially owns 75,308 shares of Acrivon common stock in direct ownership.
Acrivon Therapeutics, Inc. insiders report routine share withholding for taxes. President and CEO Dr. Peter Blume-Jensen reported that on 11/21/2025, 19,904 shares of common stock were disposed of at $2.30 per share, identified as shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units. Following this transaction, he beneficially owned 2,046,771 shares directly and 314,706 shares indirectly.
The indirect holdings reflect spousal ownership between co-founders Dr. Blume-Jensen and EVP – Business Operations Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest, which clarifies how their combined economic exposure to Acrivon’s stock is reported.
Acrivon Therapeutics, Inc. (ACRV) reported an administrative insider transaction by its Chief Accounting Officer. On 11/14/2025, 99 shares of common stock were withheld by the company at a price of $2.24 per share to cover mandatory tax withholding upon the vesting of restricted stock units. After this tax-related share withholding, the officer beneficially owned 4,122 shares of Acrivon common stock directly.
Acrivon Therapeutics, Inc. reported an insider equity transaction involving its Chief Legal Officer. On 11/14/2025, 184 shares of common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.
After this tax withholding event, the reporting officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held directly. The Form 4 is filed by a single reporting person and reflects routine equity compensation administration for the officer role.
Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer. On 11/14/2025, 403 shares of Acrivon Therapeutics common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being an open-market sale. Following this withholding event, the officer beneficially owned 15,283 shares of Acrivon Therapeutics common stock, held directly.
Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer. On 11/14/2025, 613 shares of Acrivon common stock were withheld at a price of $2.24 per share to cover mandatory tax withholding when restricted stock units vested. After this tax-related withholding, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership. The filing is administrative in nature and reflects standard equity compensation and tax settlement practices for a senior executive.
Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.
Acrivon Therapeutics (ACRV) insider activity: The Chief Legal Officer reported a routine tax-withholding event tied to restricted stock unit vesting. On 10/17/2025, a Form 4 shows transaction code F, where 558 shares of common stock were withheld by the issuer at $1.81 to satisfy mandatory taxes. After this administrative transaction, the officer directly beneficially owns 34,739 shares.
Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as acquired (Transaction Code A), leaving the reporting person with 225,000 derivative securities beneficially owned following the transaction. The filing states vesting terms: 25% vests on November 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a non-derivative disposition on 10/01/2025. The filing shows 284 shares of common stock were disposed at a price of $1.81 per share. The form states the shares were withheld by the issuer to satisfy mandatory tax withholding upon the vesting of restricted stock units. After the reported transaction, Ms. Miller beneficially owns 35,297 shares, held directly. The Form 4 was signed by attorney-in-fact Adam D. Levy on 10/03/2025.